Palisade Bio initiated the global Phase 2b ASCENTRA-UC trial for PALI-2108, an oral treatment for ulcerative colitis, dosing the first patient in October 2026. The trial aims to enroll about 204 patients and evaluate clinical remission at 12 weeks, with topline results expected in Q4 2027. The company also received FDA clearance for a Phase 2a trial in Crohn's disease, targeting enrollment in Q1 2027. With $113.6 million in cash, Palisade is well-funded to advance these programs, aiming to develop a once-daily oral therapy for inflammatory bowel disease.
Palisade Bio's recent financial results and clinical trial advancements provide context for health sector activity. For readers following the health sector, here is Pluang's market snapshot as of Nov 11, 2026 04:02 WIB: out of 150 priced US health stocks, 52 rose and 97 fell. Notable movers include NUWE at USD 5.27 with a 6.68% gain and 100% sell order activity, Moderna (MRNA) at USD 251.19 down 6.62% with 55% buy activity, and Recursion Pharmaceuticals (RXRX) at USD 3.56 down 6.44% with 100% buy order activity.
Cannabis Strategic Ventures has finalized its change of control with Scopien Technologies, an AI platform company, which now holds voting control through preferred stock. The company has appointed new leadership, including CEO Zameer Mulla, and plans...
Star Bulk Carriers Corp. has published its 2025 Environmental, Social and Governance (ESG) Report, its eighth annual report detailing the company's sustainability strategy, performance, and future objectives. The report, guided by the ESG Committee, ...
TELA Bio reported $19 million revenue in Q3 2026, down 8% year-over-year but with an 18% increase in international sales. The company reduced its operating loss by 21% sequentially and improved adjusted EBITDA loss by 55%, driven by a strategic cost ...
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
